Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - lanatoside c - tablets

United States - English - NLM (National Library of Medicine)

exelan pharmaceuticals, inc. - lanreotide acetate (unii: ieu56g3j9c) (lanreotide - unii:0g3de8943y) - lanreotide injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. the goal of treatment in acromegaly is to reduce growth hormone (gh) and insulin growth factor-1 (igf-1) levels to normal. lanreotide injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (gep-nets) to improve progression-free survival. lanreotide injection is contraindicated in patients with history of a hypersensitivity to lanreotide. allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide [see adverse reactions (6.3)] . risk summary limited available data based on postmarketing case reports with lanreotide injection use in pregnant women are not sufficient to determine a drug-associated risk of adverse dev

United States - English - NLM (National Library of Medicine)

cipla usa inc. - lanreotide acetate (unii: ieu56g3j9c) (lanreotide - unii:0g3de8943y) - lanreotide injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. the goal of treatment in acromegaly is to reduce growth hormone (gh) and insulin growth factor-1 (igf-1) levels to normal. lanreotide injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (gep-nets) to improve progression-free survival. lanreotide injection is contraindicated in patients with history of a hypersensitivity to lanreotide. allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide [ see adverse reactions (6.3)] . risk summary limited available data based on post-marketing case reports with lanreotide use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmenta

Israel - English - Ministry of Health

medison pharma ltd - lanreotide as acetate - solution for injection - lanreotide as acetate 60 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.somatuline autogel is also indicated for the treatment of grade 1 and a subset of grade 2 (ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (gep-nets) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.

Israel - English - Ministry of Health

medison pharma ltd - lanreotide as acetate - solution for injection - lanreotide as acetate 90 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.somatuline autogel is also indicated for the treatment of grade 1 and a subset of grade 2 (ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (gep-nets) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.

Israel - English - Ministry of Health

medison pharma ltd - lanreotide as acetate - solution for injection - lanreotide as acetate 120 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.somatuline autogel is also indicated for the treatment of grade 1 and a subset of grade 2 (ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (gep-nets) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lanreotide acetate 149.4mg equivalent to lanreotide 120 mg - solution for injection - 120 mg - active: lanreotide acetate 149.4mg equivalent to lanreotide 120 mg excipient: glacial acetic acid water for injection - treatment of acromegaly when circulating levels of gh and igf-1 remain abnormal after surgery and/or radiotherapy, or in patients who are dopamine agonist treatment refractory. treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lanreotide acetate 77.9mg equivalent to lanreotide 60 mg - solution for injection - 60 mg - active: lanreotide acetate 77.9mg equivalent to lanreotide 60 mg excipient: glacial acetic acid water for injection - treatment of acromegaly when circulating levels of gh and igf-1 remain abnormal after surgery and/or radiotherapy, or in patients who are dopamine agonist treatment refractory. treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lanreotide acetate 113.6mg equivalent to lanreotide 90 mg - solution for injection - 90 mg - active: lanreotide acetate 113.6mg equivalent to lanreotide 90 mg excipient: glacial acetic acid water for injection - treatment of acromegaly when circulating levels of gh and igf-1 remain abnormal after surgery and/or radiotherapy, or in patients who are dopamine agonist treatment refractory. treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 66.67 mg (equivalent: lanreotide, qty 60 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.